Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Operating Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Operating Expenses for 6 consecutive years, with $26.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 29.3% to $26.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $146.1 million, a 6.18% increase, with the full-year FY2025 number at $146.1 million, up 6.18% from a year prior.
  • Operating Expenses was $26.4 million for Q4 2025 at TScan Therapeutics, down from $39.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $41.7 million in Q2 2025 to a low of $9.9 million in Q1 2021.
  • A 5-year average of $26.9 million and a median of $28.2 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 144.66% in 2021, then decreased 29.3% in 2025.
  • TScan Therapeutics' Operating Expenses stood at $17.1 million in 2021, then grew by 27.49% to $21.7 million in 2022, then soared by 31.38% to $28.6 million in 2023, then soared by 30.84% to $37.4 million in 2024, then fell by 29.3% to $26.4 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Operating Expenses are $26.4 million (Q4 2025), $39.6 million (Q3 2025), and $41.7 million (Q2 2025).